ArticleJournal of thoracic disease2018

J-ALEX trial will crown alectinib as the standard choice for anaplastic lymphoma kinase positive untreated non-small cell lung cancer patients?

Cesare Gridelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.